Found: 115
Select item for more details and to access through your institution.
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 6, p. 1569, doi. 10.1007/s00432-019-02862-x
- By:
- Publication type:
- Article
Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2015, v. 141, n. 1, p. 43, doi. 10.1007/s00432-014-1787-z
- By:
- Publication type:
- Article
Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain.
- Published in:
- Clinical & Translational Oncology, 2024, v. 26, n. 4, p. 985, doi. 10.1007/s12094-023-03338-8
- By:
- Publication type:
- Article
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.
- Published in:
- Clinical & Translational Oncology, 2024, v. 26, n. 2, p. 352, doi. 10.1007/s12094-023-03262-x
- By:
- Publication type:
- Article
Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
- Published in:
- Clinical & Translational Oncology, 2023, v. 25, n. 5, p. 1252, doi. 10.1007/s12094-022-03046-9
- By:
- Publication type:
- Article
Biological markers of cisplatin resistance in advanced testicular germ cell tumours.
- Published in:
- Clinical & Translational Oncology, 2012, v. 14, n. 6, p. 452, doi. 10.1007/s12094-012-0823-1
- By:
- Publication type:
- Article
Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
- Published in:
- Clinical & Translational Oncology, 2012, v. 14, n. 5, p. 338, doi. 10.1007/s12094-012-0806-2
- By:
- Publication type:
- Article
Expression of EGFR, HER-2/ neu and KIT in germ cell tumours.
- Published in:
- Clinical & Translational Oncology, 2010, v. 12, n. 6, p. 443, doi. 10.1007/s12094-010-0532-6
- By:
- Publication type:
- Article
Inhibiting PI3K as a therapeutic strategy against cancer.
- Published in:
- Clinical & Translational Oncology, 2009, v. 11, n. 9, p. 572, doi. 10.1007/s12094-009-0407-x
- By:
- Publication type:
- Article
Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.
- Published in:
- Clinical & Translational Oncology, 2009, v. 11, n. 7, p. 446, doi. 10.1007/s12094-009-0383-1
- By:
- Publication type:
- Article
SEOM guidelines for the management of non-small-cell lung cancer (NSCLC).
- Published in:
- Clinical & Translational Oncology, 2009, v. 11, n. 5, p. 284, doi. 10.1007/s12094-009-0356-4
- By:
- Publication type:
- Article
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
- Published in:
- Clinical & Translational Oncology, 2008, v. 10, n. 12, p. 831, doi. 10.1007/s12094-008-0297-3
- By:
- Publication type:
- Article
Randomized Study of Cefepime versus Ceftazidime plus Amikacin in Patients with Solid Tumors Treated with High Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia.
- Published in:
- Clinical & Translational Oncology, 2006, v. 8, n. 12, p. 889, doi. 10.1007/s12094-006-0152-3
- By:
- Publication type:
- Article
Envolving treatment of fever and neutropenia in cancer patients.
- Published in:
- Clinical & Translational Oncology, 2002, v. 4, n. 6, p. 297, doi. 10.1007/BF02832104
- By:
- Publication type:
- Article
Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 5, p. 2538, doi. 10.3390/ijms22052538
- By:
- Publication type:
- Article
Identification of Oxidative Stress Related Proteins as Biomarkers for Lung Cancer and Chronic Obstructive Pulmonary Disease in Bronchoalveolar Lavage.
- Published in:
- International Journal of Molecular Sciences, 2013, v. 14, n. 2, p. 3440, doi. 10.3390/ijms14023440
- By:
- Publication type:
- Article
Erratum to: The role of pharmacogenomics in metastatic renal cell carcinoma.
- Published in:
- 2013
- By:
- Publication type:
- Correction Notice
The role of pharmacogenomics in metastatic renal cell carcinoma.
- Published in:
- Cancer & Metastasis Reviews, 2012, v. 31, p. 29, doi. 10.1007/s10555-012-9356-x
- By:
- Publication type:
- Article
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.
- Published in:
- Cancer & Metastasis Reviews, 2010, v. 29, p. 1, doi. 10.1007/s10555-010-9231-6
- By:
- Publication type:
- Article
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations.
- Published in:
- Cancer & Metastasis Reviews, 2010, v. 29, p. 11, doi. 10.1007/s10555-010-9232-5
- By:
- Publication type:
- Article
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 7, p. 1365, doi. 10.3390/jcm10071365
- By:
- Publication type:
- Article
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2018, v. 37, n. 1, p. N.PAG, doi. 10.1186/s13046-018-0871-7
- By:
- Publication type:
- Article
Down-regulation of spinophilin in lung tumours contributes to tumourigenesis.
- Published in:
- Journal of Pathology, 2011, v. 225, n. 1, p. 73, doi. 10.1002/path.2905
- By:
- Publication type:
- Article
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 2, p. 198, doi. 10.1007/s10637-016-0410-3
- By:
- Publication type:
- Article
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 357, doi. 10.1007/s10637-014-0192-4
- By:
- Publication type:
- Article
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 6, p. 1073, doi. 10.1007/s10147-021-01899-8
- By:
- Publication type:
- Article
Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation- Positive Metastatic Non—Small-Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non--Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2014, v. 15, n. 6, p. 418, doi. 10.1016/j.cllc.2014.06.007
- By:
- Publication type:
- Article
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or...
- Published in:
- Clinical Lung Cancer, 2012, v. 13, n. 6, p. 500, doi. 10.1016/j.cllc.2012.05.009
- By:
- Publication type:
- Article
Targeting KRAS<sup>G12C</sup> in Non-Small-Cell Lung Cancer: Current Standards and Developments.
- Published in:
- Drugs, 2024, v. 84, n. 5, p. 527, doi. 10.1007/s40265-024-02030-7
- By:
- Publication type:
- Article
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Targeting EGFR in Lung Cancer: Current Standards and Developments.
- Published in:
- Drugs, 2018, v. 78, n. 9, p. 893, doi. 10.1007/s40265-018-0916-4
- By:
- Publication type:
- Article
Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer.
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0119878
- By:
- Publication type:
- Article
Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry.
- Published in:
- PLoS ONE, 2014, v. 9, n. 9, p. 1, doi. 10.1371/journal.pone.0107200
- By:
- Publication type:
- Article